Accellta was founded 12 years ago with a mission to revolutionize the cultivation and manufacturing of stem cells. Stem cells are cells that can differentiate into various specialized cell types and have the unique capability of undergoing unlimited cell divisions. For that reason, Stem cells carry vast potential for various applications in the biotech and food-tech industries. Accellta’s unique proprietary 3D suspension culture platform, addresses the critical scalability bottleneck that has long hindered progress in this field. It ensures large-scale production and affordable end-products encompassing chemically defined media and proprietary stable cell lines derived from humans, aquatic animals and farm animal. Since 2018, the company has demonstrated stable profitability, resulting from various services and products they provide and trusted partnerships with global industry leaders like Stem Cell Technologies, Ajinomoto, and Hitachi Chemicals. Driven by innovation, Accellta has secured over 120 patents across 11 patent families, solidifying its position as an important player in the stem cell space. The company is in the process of capital raising to propel scaling up capabilities for the evolving food tech industry.